Compartir
array:23 [ "pii" => "S021056911630105X" "issn" => "02105691" "doi" => "10.1016/j.medin.2016.05.009" "estado" => "S300" "fechaPublicacion" => "2016-10-01" "aid" => "942" "copyright" => "Elsevier España, S.L.U. y SEMICYUC" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Med Intensiva. 2016;40:434-47" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4128 "formatos" => array:3 [ "EPUB" => 160 "HTML" => 2742 "PDF" => 1226 ] ] "itemSiguiente" => array:18 [ "pii" => "S0210569116000139" "issn" => "02105691" "doi" => "10.1016/j.medin.2015.12.006" "estado" => "S300" "fechaPublicacion" => "2016-10-01" "aid" => "878" "copyright" => "Elsevier España, S.L.U. y SEMICYUC" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Intensiva. 2016;40:448-50" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6185 "formatos" => array:3 [ "EPUB" => 191 "HTML" => 4811 "PDF" => 1183 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICA</span>" "titulo" => "Pacientes críticos al final de la vida: estudio multicéntrico en Unidades de Cuidados Intensivos españolas" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "448" "paginaFinal" => "450" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "End of life critical patients: A multicenter study in Spanish Intensive Care Units" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Estella, M.C. Martín, A. Hernández, O. Rubio, J.L. Monzón, L. Cabré" "autores" => array:7 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Estella" ] 1 => array:2 [ "nombre" => "M.C." "apellidos" => "Martín" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Hernández" ] 3 => array:2 [ "nombre" => "O." "apellidos" => "Rubio" ] 4 => array:2 [ "nombre" => "J.L." "apellidos" => "Monzón" ] 5 => array:2 [ "nombre" => "L." "apellidos" => "Cabré" ] 6 => array:1 [ "colaborador" => "Grupo de trabajo bioética SEMICYUC" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210569116000139?idApp=WMIE" "url" => "/02105691/0000004000000007/v1_201609190011/S0210569116000139/v1_201609190011/es/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0210569116300596" "issn" => "02105691" "doi" => "10.1016/j.medin.2016.04.003" "estado" => "S300" "fechaPublicacion" => "2016-10-01" "aid" => "923" "copyright" => "Elsevier España, S.L.U. y SEMICYUC" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Med Intensiva. 2016;40:431-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7799 "formatos" => array:3 [ "EPUB" => 191 "HTML" => 6254 "PDF" => 1354 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Punto de vista</span>" "titulo" => "Reflexiones sobre la donación en asistolia controlada (donantes tipo <span class="elsevierStyleSmallCaps">III</span> de Maastricht)" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "431" "paginaFinal" => "433" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Reflections upon donation after controlled cardiac death (Maastricht type <span class="elsevierStyleSmallCaps">iii</span> donors)" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.J. Rubio, D. Palacios" "autores" => array:2 [ 0 => array:2 [ "nombre" => "J.J." "apellidos" => "Rubio" ] 1 => array:2 [ "nombre" => "D." "apellidos" => "Palacios" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173572716300340" "doi" => "10.1016/j.medine.2016.04.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173572716300340?idApp=WMIE" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210569116300596?idApp=WMIE" "url" => "/02105691/0000004000000007/v1_201609190011/S0210569116300596/v1_201609190011/es/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special article</span>" "titulo" => "Blood purification in the critically ill patient. Prescription tailored to the indication (including the pediatric patient)" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "434" "paginaFinal" => "447" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J.A. Sanchez-Izquierdo Riera, R. Montoiro Allué, T. Tomasa Irriguible, E. Palencia Herrejón, F. Cota Delgado, C. Pérez Calvo" "autores" => array:6 [ 0 => array:4 [ "nombre" => "J.A." "apellidos" => "Sanchez-Izquierdo Riera" "email" => array:1 [ 0 => "jasiruci@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "R." "apellidos" => "Montoiro Allué" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "T." "apellidos" => "Tomasa Irriguible" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "E." "apellidos" => "Palencia Herrejón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "F." "apellidos" => "Cota Delgado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "C." "apellidos" => "Pérez Calvo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "Intensive Care Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Intensive Care Medicine, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Intensive Care Medicine, Hospital Germans Trias i Pujol, Badalona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Intensive Care Medicine, Hospital Universitario Infanta Leonor, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Intensive Care Medicine, Hospital Clínico Virgen de la Victoria, Málaga, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Intensive Care Medicine, Hospital Fundación Jiménez Díaz, Madrid, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Depuración de la sangre en el enfermo crítico. Prescripción adaptada a la indicación (incluido el paciente pediátrico)" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 4253 "Ancho" => 2642 "Tamanyo" => 568755 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">HVHF management algorithm in unstable critically ill patients. SIRS: systemic inflammatory response syndrome. CVP: central venous pressure. S<span class="elsevierStyleInf">cv</span>O2: Venous oxygen saturation. ICU: Intensive Care Unit. SOFA: SOFA Score. AKI: Acute kidney injury. CRRT: Continuous extracorporeal blood purification therapies. NA/NE: Noradrenaline. CVVHDF: Continuous venovenous hemodiafiltration. Q<span class="elsevierStyleInf">efl</span>: Effluent flow. EBPT: extracorporeal blood purification therapies. CVVH: Continuous venovenous hemofiltration. HVHF: high volume hemofiltration. Q<span class="elsevierStyleInf">subst:</span> Effluent flow. EBPT: Extracorporeal blood purification therapies.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Acute kidney injury (AKI) is a common and serious problem for the intensive care unit (ICU) patient. In a study undertaken by the Nephrointensive Care Working Group of the Spanish society of intensive care (SEMICYUC) that covered 43 ICUs,<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">1</span></a> the reported incidence for AKI was 5.6% (a figure that increased up to 8.6% when coronary patients were excluded) and in a high percentage of patients, AKI developed as a component of the multiorgan dysfunction syndrome (MODS) (up to 93% in this study).</p><p id="par0010" class="elsevierStylePara elsevierViewall">For the last 25 years we have witnessed dramatic changes in the way we manage extracorporeal blood purification therapies (EBPT) in the critically ill. Probably the key of these changes remains in a change in the goals pursued with the treatment and is reflected mainly by a shift from the classic view of purification<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">2</span></a> to a more preemptive role in the critically ill patient (CIP), when we aim now to minimize the negative impact of AKI in the evolution of MODS. This new focus (that we prefer to refer to as “renal support” instead of the more limited concept of “renal purification”) explains also why continuous extracorporeal blood purification therapies (CEBPT) have positioned in the last years as a cornerstone in the field of EBPT in the ICU. In the above mentioned Spanish study<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">1</span></a> 38% of the patients with AKI received EBPT and 84% continuous modalities were used.</p><p id="par0015" class="elsevierStylePara elsevierViewall">This preference can be explained by different circumstances<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">3,4</span></a>: there is a good hemodynamic tolerance when a CEBPT is used (being the best alternative when hemodynamic instability precludes the use of an intermittent (IHD) modality); it is “slow”, progressive and continuous and therefore avoids the abrupt changes in intravascular volume and electrolyte concentrations that take place during IHD; since it contributes to a lower but continuous elimination of fluid it gives us more room for the administration of parenteral nutrition and intravenous medication, besides providing for a selective removal from the interstitial space; the circuits have a small extracorporeal priming volume and show a lower activation of the complement system (mainly because the use of more biocompatible membranes); and finally because of the low rate of complications reported with its use. And besides all these facts, CEBPT can be safely applied by nursing staff with regular ICU training without requiring specialized staff for IHD.</p><p id="par0020" class="elsevierStylePara elsevierViewall">In this review we will develop an update of the different scenarios where EBPT can be indicated and will distinguish between pure renal indications from other possible “non renal” scenarios for its use.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Indications and timing of renal EBPT (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>)</span><p id="par0025" class="elsevierStylePara elsevierViewall">The classic scenario for initiation of an EBPT, as collected in the Kidney Disease Outcomes Quality Initiative guidelines (KDIGO)<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">5</span></a> and the European Renal Best Practice (ERBP) position statement on the KDIGO,<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">6</span></a> makes reference to the urgent indication when the electrolyte abnormalities, acid–base balance, azotemia and fluid overload compromise life.<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0030" class="elsevierStylePara elsevierViewall">Initiate EBPT when life-threatening fluid overload, electrolyte and acid–base misbalances are present that cannot be corrected in a conservative way. (Not Graded)</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0035" class="elsevierStylePara elsevierViewall">When deciding on the initiation of an EBPT, the clinical context for each individual case must be taken into consideration as well as lab-test trends and how these can be modified by the EBPT, instead of a fixed value for a specific blood marker (i.e. urea or creatinine). (Not Graded)</p></li></ul></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">In any case, the ideal timeframe to initiate EBPT in the critically ill AKI patient is still undecided and a matter of continuous debate. It still remains controversial whether a “precocious vs late” indication could impact mortality or renal recovery in our patients. Furthermore, the terms precocious and late are subjective and as such are defined in different ways in the published studies. Right now a recommendation can not be made because we lack a clear reference, however, there is a trend to initiate them early based on several studies with methodology limitations and seems more clear that avoiding its use or delaying its initiation has some impact on mortality and can increase ICU stay.<a class="elsevierStyleCrossRefs" href="#bib0410"><span class="elsevierStyleSup">7–10</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">An additional problem remains in the impossibility to estimate the chances for AKI recovery regardless of the EBPT use and this makes harder the decision about when (or if) initiate the treatment.<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">11</span></a> Several renal biomarkers might be useful if prove to be able to detect which patients will most probably recover before<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">12</span></a> or after<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">13</span></a> the initiation of the EBPT. In this context, it is possible that a furosemide test could be useful in predicting which patients will advance to a more severe stage of AKI.<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">14</span></a> Consequently, until high quality evidence (i.e. RCT)<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">9,15,16</span></a> is at our disposal a recommendation of early vs late initiation of the EBPT cannot be made.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Therefore, if we take into consideration the evidence already published, we can define two approaches to the initiation of EBPT in AKI: (1) when there is an “absolute indication” as acute refractory cardiogenic pulmonary edema, toxic hyperkalemia or uremic symptoms and (2) when we consider a “precocious indication” as have been indicated by a urea over 120<span class="elsevierStyleHsp" style=""></span>mg/dL, BUN over 60<span class="elsevierStyleHsp" style=""></span>mg/dL, creatinine over 1.5 times the baseline, decrease of the creatinine clearance below 25%, diuresis less than 200<span class="elsevierStyleHsp" style=""></span>mL/12<span class="elsevierStyleHsp" style=""></span>h, metabolic acidosis, lactic acidosis or moderate-severe hyperkalemia (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">17</span></a>We have even less information about the timing for withdrawal of EBPT. Of course it is sensible withdrawing the treatment once the kidneys show enough improvement in function, however, the key question is how define improvement in function while EBPT is running. Observational studies have shown that the most important predictor for a successful withdrawal of EBPT is a sufficient production of urine. An urine output over 400<span class="elsevierStyleHsp" style=""></span>mL/day without diuretics administration is a reasonable parameter, resulting in a correct decision in over 79% of cases.<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">18</span></a> Another approach can be the estimation of glomerular filtration rate but the precise level of endogenous creatinine clearance necessary for a successful withdrawal of renal support has not yet been established but it is assumed to be between 15 and 20<span class="elsevierStyleHsp" style=""></span>mL/min.<a class="elsevierStyleCrossRef" href="#bib0470"><span class="elsevierStyleSup">19</span></a></p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0055" class="elsevierStylePara elsevierViewall">We, therefore, advocate for a dynamic approach when prescribing a EBPT, similar to the way we work with, for example, mechanical ventilation.<a class="elsevierStyleCrossRefs" href="#bib0460"><span class="elsevierStyleSup">17,20</span></a> For this approach to be successful we must count on a (daily) “check-list” of therapeutic objectives (addressing internal environment and volume status, either) for guidance in tapering the delivered dose until we can confidently suspend the EBPT<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">21</span></a> (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). Once the patient is capable by itself to maintain the internal milieu homeostasis and fluid balance without EBPT, we can definitively finish the treatment.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Modalities of renal extracorporeal blood purification therapies</span><p id="par0060" class="elsevierStylePara elsevierViewall">A significant number of CIP with AKI will require the implementation of an intermittent or continuous EBPT<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">5</span></a> and the first step will be precisely the choice between one of them (intermittent vs continuous, in their different modalities). This decision will be based on the availability and the experience of the medical team, the hemodynamic status and characteristics and underlying pathology of the patient. It seems clear nowadays that peritoneal dialysis has been superseded in critically ill adult patients and it will only be used when other methods are not available. As discussed earlier when addressing the dynamic approach for the indication and management of EBPT, another aspect to be considered is the shifting between modalities to fit them to the clinical (and changing) situation of each individual patient (hemodynamic status, blood clotting problems, etc.).<a class="elsevierStyleCrossRefs" href="#bib0400"><span class="elsevierStyleSup">5,6</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Over 20 clinical trials and more than 5 meta-analyses have been published analyzing differences between IHD and various modalities of CEBPT in the CIP, looking after mortality or renal recovery as main outcome<a class="elsevierStyleCrossRefs" href="#bib0485"><span class="elsevierStyleSup">22,23</span></a> but besides the fact that CEBPT facilitates the management of the instable patients none of those modalities has proven superiority over the others.</p><p id="par0070" class="elsevierStylePara elsevierViewall">We can argue that, due to the sudden changes in the distribution of fluids between body compartments following the fast removal of liquids propitiated by IHD, CEBPT seem to be the best option for the hemodynamically unstable patient.<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">3,6</span></a> This is because the osmolar disequilibrium that IHD induces (with the shift of water that ensues), continuous modalities must be used in patients with brain injury,<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">3,6</span></a> as a matter of fact a slower change in solutes and water avoids negative effects on intracranial pressure. On the other side, the rapid elimination of toxins occurring in the IHD, makes this procedure the suitable choice in cases of toxic hyperkalemia, poisoning or tumor lysis syndrome (recommendation not graded). Furthermore, a lower requirement for anticoagulation on the extracorporeal circuit during IHD, and the short period of time during which it is running confreres certain advantages for the intermittent over the continuous modalities. For examples, IHD seems more suited for bleeding patients with coagulopathy or patients subjected to frequent diagnostic and/or therapeutic interventions, involving the need for hospital transfers (not graded).</p><p id="par0075" class="elsevierStylePara elsevierViewall">But as a whole, despite the fact that some studies have shown a tendency toward a better evolution of the patients treated with some of the continuous techniques, and taking into consideration the methodological flaws detected in all the RCT referred previously, we must conclude that both (intermittent and continuous) are equivalent therapies and that, as a result, there is no ideal universal method for all our patients and, in addition to this, that there is no ideal method for a single patient during the entire process of the disease. So, once more, the choice between different modalities of EBPT must be continuously adapted to the clinical condition of our patients.<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">20</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">As for the “hybrid therapies”, the fact is that there are no studies comparing them with IHD and the few that compare them with CEBPT do not show homogeneous results. Moreover, there is fewer experience reported with this modality than with intermittent or continuous modalities.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Dosing the extracorporeal purification therapy</span><p id="par0085" class="elsevierStylePara elsevierViewall">Given the complexity of the CIP that develops AKI, it has been argued the possibility that implementing a EBPT and adjusting the delivered dose may have a low impact on the outcome for those patients that show the lesser and highest severity (i.e. those that will probably recover or die whatever we try) but could make a difference for the group of intermediate severity.<a class="elsevierStyleCrossRefs" href="#bib0400"><span class="elsevierStyleSup">5,6</span></a> It is for this group that a dynamic tailoring of the dose to the patient's clinical condition seems more reasonable.<a class="elsevierStyleCrossRefs" href="#bib0460"><span class="elsevierStyleSup">17,20,21</span></a> In addition, it is possible that this group would benefit the most of a timely initiation of the therapy (before the patient becomes too ill). We believe that EBPT dose should be decided on the basis of the clinical condition (before actually initiating the therapy) and should be frequently reevaluated to adjust continuously the prescription.<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">6</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">When prescribing a CEBPT, the dose must be calculated in mL/kg/h of effluent obtained (not graded) starting with a recommended dose of at least 30<span class="elsevierStyleHsp" style=""></span>mL/kg/h.<a class="elsevierStyleCrossRefs" href="#bib0400"><span class="elsevierStyleSup">5,17</span></a> We must take into consideration that the delivered dose is more often than not below the proposed initially (unavoidable down runtime because different causes) and hence we recommend to begin with a dose between 30 and 35<span class="elsevierStyleHsp" style=""></span>mL/kg/h. After this initial prescription is ongoing, we suggest to re-evaluate daily the hemodynamic, metabolic and water status in order to adjust the dose consequently (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).<a class="elsevierStyleCrossRefs" href="#bib0460"><span class="elsevierStyleSup">17,20,21</span></a> Likewise, it is necessary to readjust the dosage of those prescribed drugs that are cleared by the EBPT according to the changes in its dosage.<a class="elsevierStyleCrossRefs" href="#bib0400"><span class="elsevierStyleSup">5,6,17</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">When prescribing an IHD or hybrid therapy, some disputes persist regarding dosage. According to the KDIGO guidelines and its adaptation by the Scientific Society of Oceania the recommended prescription amounts to a Kt/Vd (K: urea clearance of the hemofilter; t: duration of the session; Vd: volume of distribution of urea) of 3.9 per week<a class="elsevierStyleCrossRefs" href="#bib0400"><span class="elsevierStyleSup">5,22</span></a> but in regard that Kt/Vd has only been validated for chronic renal patients (rather different from critically ill patients with AKI developing often as part of a MODS) and that this estimate monitors the efficiency of the therapy only based on urea kinetics, the European Renal Best Practices – ERBP – does not recommended Kt/Vd but instead to adjust the dose to the metabolic and body water requirements of the patient as proposed in different studies.<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">6</span></a></p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Other “non renal” possible indications for EBPT</span><p id="par0100" class="elsevierStylePara elsevierViewall">Since the beginning of the use of these techniques, some additional benefits apart from those directly derived from the normalization of the internal milieu have been considered in the CIP setting. In this regard, some data point to the possibility that CEBPT could influence favorably the clinical course and, possibly, the outcome of these patients, even in absence of AKI (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Role of CEBPT in fluid overload</span><p id="par0105" class="elsevierStylePara elsevierViewall">Managing fluid overload is difficult in unstable patients. It is a real challenge to regulate intravascular and extravascular volume, especially in patients in septic shock. An early and adequate resuscitation followed by a subsequent conservative fluid strategy has been shown to be associated with significant improvement in outcome<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">23</span></a> and fluid overload has been proven an independent predictor of mortality in CIP and is now considered an undesirable effect of resuscitation strategies. However on the other side, aggressive removal of excess fluid can prove a difficult task and even contribute to hypovolemia, increasing vasopressors needs and exposing the patients to an unnecessary risk resultant from beta and alpha receptor stimulation.<a class="elsevierStyleCrossRef" href="#bib0495"><span class="elsevierStyleSup">24</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">Fluid removal by ultrafiltration, unlike the effect of diuretics, has the capability to extract volume both from the intravascular and the interstitial compartment at a similar rate due to an isotonic “dehydration” that promotes a continuous intravascular refilling from the interstitial compartment at the same rate as the fluid is extracted from the body. As long as this refilling capability is maintained the fluid extraction will be well tolerated.Slow continuous ultrafiltration (SCUF) is a CEBPT modality that aims to remove excess fluid and for its use requires a low convective and blood flows (50–100<span class="elsevierStyleHsp" style=""></span>mL/min) by means of a highly permeable filter and without need for replacement fluid. SCUF has shown some utility in patients with acute cardio-renal syndrome once tubular drug-resistance ensues.<a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">25</span></a> A “classic” study<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">26</span></a> has shown how daily sessions of fixed dosed SCUF have a positive impact on survival of CIP with congestive heart failure and, not less important, on their perception of quality of life. Bart et al.<a class="elsevierStyleCrossRef" href="#bib0510"><span class="elsevierStyleSup">27</span></a> carried out a controlled pilot study (RAPID-CHF), including 40 patients with congestive heart failure (20 patients treated conventionally vs 20 implementing conventional treatment plus ultrafiltration) that proved that SCUF provides significantly more fluid removal than the conventional treatment and higher relief of the cardiac failure symptomatology. In this same line, Constanzo et al.,<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">28</span></a> in a controlled study including 200 patients with congestive heart failure (UNLOAD), compared the clinical evolution between patients receiving conventional treatment with others that were managed exclusively with SCUF. The main result was a superior fluid removal in the SCUF group, with a longer symptom-free and hospitalization period. More recently, the ULTRADISCO study, published in 2011,<a class="elsevierStyleCrossRef" href="#bib0520"><span class="elsevierStyleSup">29</span></a> demonstrated in 30 decompensated heart failure patients that SCUF, compared with intravenous diuretics, didn’t only achieve a greater clinical improvement, but also showed a significant improvement in a number of hemodynamic parameters.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Nevertheless, in 2012 the continuation of the pilot experience by Bart et al., known as the CARRESS-HF study, was published,<a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">30</span></a> this time with negative results. The study has been criticized due to several methodological problems: i.e. fixed SCUF dosage (200<span class="elsevierStyleHsp" style=""></span>mL/h), authors do not use on line hematocrit neither hemodynamic parameters for guiding dosage, patients with Cr<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>3.5 and use of vasodilators and inotropic agents are excluded (those who would have benefited more from SCUF), the definition of overload is not very reliable (CVP<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>10, leg edema, etc.), and introduced combined end points.</p><p id="par0120" class="elsevierStylePara elsevierViewall">Waiting for new studies that clarify the role of SCUF and from the point of view of a dynamic approach in the management of the critically ill patient, to include parameters of hemodynamic tolerance and refilling capability in order to adjust the “dehydration rate” of our patients can make of SCUF an emerging, effective and safe option for the handling of serious fluid overload, especially in hemodynamically unstable patients.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Acute hepatic failure</span><p id="par0125" class="elsevierStylePara elsevierViewall">There are different case series in the literature reporting the use of CEBPT as a component in the management of hepatic encephalopathy in the context of fulminant hepatic failure.<a class="elsevierStyleCrossRef" href="#bib0530"><span class="elsevierStyleSup">31</span></a> Nowadays specific techniques of extracorporeal depuration for liver failure could increase the apparent benefits of these techniques.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Intoxications</span><p id="par0130" class="elsevierStylePara elsevierViewall">EBPT is the treatment of choice when an intoxication is accompanied by electrolyte imbalances, AKI or hemodynamic instability. The use of a continuous technique supposes an additional benefit preventing the rebound effects of some intoxications as lithium, valproic acid, N-acetil procainamide, methotrexate, teophylline and metformin.<a class="elsevierStyleCrossRef" href="#bib0535"><span class="elsevierStyleSup">32</span></a> Experts recommend EBPT at lactate concentrations >20<span class="elsevierStyleHsp" style=""></span>mmol/L or pH ≤7.2, in case of shock or decreased level of consciousness, and when standard supportive measures fail.<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">33</span></a> CEBPT is thought to be physiologically more appropriate than IHD, mainly because its large volume of distribution within a two-compartment pharmacokinetic model that implies that metformine may be more effectively cleared by prolonged EBPT. This was corroborated by Keller et al.<a class="elsevierStyleCrossRef" href="#bib0545"><span class="elsevierStyleSup">34</span></a> who recently showed a dramatic reduction of metabolic acidosis and decrease of metformin plasma concentration within the first 24<span class="elsevierStyleHsp" style=""></span>h after initiating CEBPT.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Metabolic acidosis</span><p id="par0135" class="elsevierStylePara elsevierViewall">Due to the already referred capability of CEBPT for removal of high amounts of fluids, these modalities enable the administration of important amounts of bicarbonate to patients with severe acidosis, diminishing the risk of hypernatremia or fluid overload. Severe lactic acidosis is now a generally accepted indication for CEBPT. The alkalosis secondary to the use of high doses of citrate as anticoagulant has been employed in some isolated reports as an adjuvant in the management of patients with acidosis.<a class="elsevierStyleCrossRef" href="#bib0550"><span class="elsevierStyleSup">35</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Hyperthermia/hypothermia</span><p id="par0140" class="elsevierStylePara elsevierViewall">Extracorporeal circuits allow for cooling or heating the patient's blood through the control of the temperature of the fluids used or the blood inside the circuit, and could be used as hyperthermia treatment or in severe and refractory to conventional treatment hypothermia. Accidental hypothermia is a problem of public health not negligible, both for its intrinsic importance, and its prognostic influence in other pathologies as severe trauma (as part of the “triangle of death” of hypothermia, coagulopathy and bleeding). While cardiopulmonary bypass is considered the most effective method for warming on severe hypothermia (central temperature <28<span class="elsevierStyleHsp" style=""></span>°C), the invasiveness of this technique makes it suitable in most cases. Another simpler option is the venovenous rewarming, which is significantly faster than conventional methods, and may be useful in certain cases.<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">3</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">CEBPT could be also used to facilitate the normo-hypothermia patient to certain diseases, such as septic shock, Out-of-Hospital Cardiac Arrest, severe brain trauma, etc.; control that could have a prognostic significance. Several authors have introduced temperature control between the criteria to indicate a CEBPT in critically ill patients.<a class="elsevierStyleCrossRef" href="#bib0555"><span class="elsevierStyleSup">36</span></a></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Electrolyte abnormality</span><p id="par0150" class="elsevierStylePara elsevierViewall">Almost any electrolyte abnormality can be successfully treated with a suitable technique combined with adequate amendments in the fluids for dialysis/replacement. CEBPT have been successfully used to treat patients with hyperkalemia, dysnatremia or hypercalcemia refractory to standard measures.<a class="elsevierStyleCrossRefs" href="#bib0390"><span class="elsevierStyleSup">3,36</span></a></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Crush syndrome</span><p id="par0155" class="elsevierStylePara elsevierViewall">Crush injury is a serious medical condition characterized for hyperkalemia, myoglobinuria and acute renal failure. The reported experience shows that with the use of adequate prophylactic measures the impact of a EBPT is minimal in the management of these patients<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">37</span></a> but when in need for its use, CEBPT based on convection can show some advantages due to its capability for removal of myoglobin (not cleared by diffusion because its molecular weight) and furthermore a more accurate control of fluid than for intermittent techniques.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Burns</span><p id="par0160" class="elsevierStylePara elsevierViewall">Acute renal failure is a common condition in patients with major burn injuries. CEBPT is generally used in patients who cannot tolerate intermittent therapies, allowing optimum control of the catabolic state and fluid handling.<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">38</span></a></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Brain edema</span><p id="par0165" class="elsevierStylePara elsevierViewall">CEBPT should be the first option for these patients since it is associated with less increase in ICP compared with intermittent therapies and is also associated with better maintenance of the auto-regulation of cerebral blood flow after traumatic brain injury. This advantage is due to a slower modification in solute concentration, avoiding large osmotic fluctuations and fluid shifts.<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">39</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Cardiac surgery</span><p id="par0170" class="elsevierStylePara elsevierViewall">Some groups have demonstrated the utility of CEBPT in patients subjected to cardiopulmonary by-pass during a cardiac surgery.<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">40,41</span></a> Indeed, this technique reduces the hemodilution that takes place during the intervention and mitigates the secondary inflammatory response, resulting in a positive effect on the hemodynamics of our patients, an effect detected in adults as much as in children, but being especially useful in the latter.</p></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">High volume hemofiltration (HVHF)</span><p id="par0175" class="elsevierStylePara elsevierViewall">The use of high doses of a convective therapy regardless of the renal function of the CIP, high volume hemofiltration (HVHF), has been advised as a mean for the elimination of inflammatory mediators and or other toxic substances. The problem for this modality is a lack of agreement over what “high volume” means. In the consensus conference of “Acute Dialysis Quality Initiative” (ADQI) held in 2002<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">42</span></a> HVHF was defined as a volume of effluent over 35<span class="elsevierStyleHsp" style=""></span>mL/kg/h but even this threshold has been challenged and 35<span class="elsevierStyleHsp" style=""></span>mL/kg/h is not to be considered high enough to CEBPT “high volume” according to current practices.</p><p id="par0180" class="elsevierStylePara elsevierViewall">In 2007, at the Pardubice Consensus Conference,<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">43</span></a> HVHF was defined as a dose greater than 50<span class="elsevierStyleHsp" style=""></span>mL/kg/h in a continuous basis or a prescription over 100<span class="elsevierStyleHsp" style=""></span>mL/kg/h as a pulse of at least 4<span class="elsevierStyleHsp" style=""></span>h/day, followed by a more conventional dose for the rest of the day (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Pathophysiological basis</span><p id="par0185" class="elsevierStylePara elsevierViewall">In severe systemic inflammatory conditions, such as sepsis or acute pancreatitis, organ dysfunction (MODS) is a common occurrence and the pathophysiological alterations involved rest in the release of various inflammatory mediators that exert a modulatory function on the response system. CEBPT and specifically HVHF can have a role as a rescue therapy and even play a central role on the resuscitation management of MODS. Different mechanisms have been proposed to explain the beneficial effect of HVHF in severe inflammatory conditions.<a class="elsevierStyleCrossRefs" href="#bib0595"><span class="elsevierStyleSup">44,45</span></a> The clearance of inflammatory mediators from the circulatory system in periods in which they show a high concentration can be effective in reducing their plasmatic peak and its derived harmful effects. Moreover, the elimination of these molecules from the blood decreases their concentration in tissues as well (where they produce tissue damage) by means of a balance between these two compartments; this effect can explain why some studies show beneficial effects without detecting any changes in the plasma concentrations of these mediators. Furthermore, an increased lymph flow induced by high fluid shifts during HVHF exerts a flushing effect at the tissue level. Finally, it has been suggested recently that HVHF can act directly on the cellular level, restoring the immune function of monocytes and neutrophils.</p><p id="par0190" class="elsevierStylePara elsevierViewall">It is important to note that along these potential beneficial effects, HVHF can also show serious side effects. It increases the losses of valuable molecules (drugs, electrolytes, vitamins or trace elements),<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">20</span></a> forcing a close monitoring of their clearance, a control difficult to perform accurately in clinical practice. Other known risks after CEBPT (anticoagulant-related hemorrhage, infection, embolism, hemodynamic intolerance) have also been reported. Complex techniques such as HVHF can compromise patient safety by multiplying the risk of errors, that may also have amplified consequences (important even in small time periods). It is therefore essential the use of these therapies with a rigorous quality and safety control.<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">46</span></a></p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Potential indications</span><p id="par0195" class="elsevierStylePara elsevierViewall">HVHF has been proposed as a mean for organ support in CIP with high risk of death, regardless of renal function, as can be (for instance) septic shock, post-resuscitation syndrome, post-surgery cardiac shock, acute pancreatitis or acute liver failure, especially when a severe hemodynamic compromise and dependence on high doses of vasoactive drugs are present, the rational resting in the clearance of circulating inflammatory mediators already discussed.</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Preclinical studies and pilot studies</span><p id="par0200" class="elsevierStylePara elsevierViewall">Various animal studies<a class="elsevierStyleCrossRefs" href="#bib0610"><span class="elsevierStyleSup">47,48</span></a> have shown that HVHF decreases the plasma concentration of inflammatory mediators and improves hemodynamics and survival in sepsis and pancreatitis. In some of them a dose–response relationship was found (greater effectiveness at higher doses and frequent changes of filter) and also a relationship with the membrane used (polyacrylonitrile being found more effective than polysulfone). Nonetheless these studies should be interpreted cautiously because of the difficulty in translating results of animal studies to the clinical practice. Many preliminary clinical studies have shown potential benefits with different techniques when comparing high versus conventional dose hemofiltration; however, these studies have considerable methodological problems.</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Evidence</span><p id="par0205" class="elsevierStylePara elsevierViewall">In line with the initial animal studies on the usefulness of HVHF for severe systemic inflammation,<a class="elsevierStyleCrossRefs" href="#bib0610"><span class="elsevierStyleSup">47,48</span></a> Journois et al. demonstrated the beneficial effect of HVHF (100<span class="elsevierStyleHsp" style=""></span>mL/kg/h) in the management of children with SIRS in postoperative cardiac surgery with cardiopulmonary bypass<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">49</span></a> but after these experiences, the use of HVHF has not demonstrated clear clinical benefits in large clinical trials. Nonetheless, experimental and preliminary clinical studies suggest that this technique can improve organ dysfunction and hemodynamics in septic shock and other clinical situations.</p><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Severe sepsis and septic shock</span><p id="par0210" class="elsevierStylePara elsevierViewall">Cole and colleagues<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">50</span></a> demonstrated in a randomized, controlled study, with a crossover design, carried out in 11 patients, that HVFV (6<span class="elsevierStyleHsp" style=""></span>L/h for 8<span class="elsevierStyleHsp" style=""></span>h) provided a clear hemodynamic benefit compared with conservative CEBP (1<span class="elsevierStyleHsp" style=""></span>L/h for 8<span class="elsevierStyleHsp" style=""></span>h). These findings were subsequently confirmed in a pilot study comparing different doses of purification (65 vs 35 vs 20<span class="elsevierStyleHsp" style=""></span>mL/kg/h) as hemodynamic optimization therapy.<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">51</span></a></p><p id="par0215" class="elsevierStylePara elsevierViewall">There are several other available studies that show positive results with the use of HVHF as a rescue therapy in severe sepsis and septic shock:</p><p id="par0220" class="elsevierStylePara elsevierViewall">Oudemans et al.<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">52</span></a> evaluated in a prospective cohort study whether HVHF had any impact on mortality of CIP and found a significantly lower mortality for these patients based on APACHE II, SAPS II and Liaño index. Honoré et al.<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">53</span></a> in a group of 20 patients with severe circulatory failure secondary to septic shock despite conventional treatment, evaluated the response to a HVHF round (35<span class="elsevierStyleHsp" style=""></span>L in 4<span class="elsevierStyleHsp" style=""></span>h). In the group of 11 “responders”, mortality was 18%, much lower than expected (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05). Furthermore, they noted that the group of “responders” was initiated with the EBP in an earlier stage and the delivered dose was significantly higher than for the “non-responders” group.</p><p id="par0225" class="elsevierStylePara elsevierViewall">In a later study from Joannes-Boyau et al.,<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">54</span></a> the use of HVHF 40–60<span class="elsevierStyleHsp" style=""></span>mL/kg/h for 96<span class="elsevierStyleHsp" style=""></span>h in 24 patients with septic shock was associated with significant hemodynamic improvement, as well as in the mortality observed at 28 days (compared with expected mortality).</p><p id="par0230" class="elsevierStylePara elsevierViewall">Ratanarat et al.<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">55</span></a> analyzed the effect of high volume “pulses” of 6–8<span class="elsevierStyleHsp" style=""></span>h of 85<span class="elsevierStyleHsp" style=""></span>mL/kg/h, followed by 16–18<span class="elsevierStyleHsp" style=""></span>h of 35<span class="elsevierStyleHsp" style=""></span>mL/kg/h in 15 patients with severe sepsis and found a positive effect on hemodynamics and expected survival.</p><p id="par0235" class="elsevierStylePara elsevierViewall">More recently, Piccinni et al.<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">56</span></a> analyzed the effect of an early pulse of 6<span class="elsevierStyleHsp" style=""></span>h HVHF (45<span class="elsevierStyleHsp" style=""></span>mL/kg/h) (within the first 12<span class="elsevierStyleHsp" style=""></span>h after admission) in septic shock patients, followed by conventional dose CEBPT. In this retrospective study of 80 CIP they found a significant hemodynamic and respiratory improvement after the initiation of HVHF.</p><p id="par0240" class="elsevierStylePara elsevierViewall">Some other authors have proposed including HVHF in the management of patients in refractory septic shock, in order to stabilize the hemodynamic status and our group has proposed a similar algorithm<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">57</span></a> (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0245" class="elsevierStylePara elsevierViewall">In an attempt to strengthen the role of HVHF, the IVOIRE European study<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">58</span></a> was launched in 2005. It was a multicenter, randomized, controlled trial in which they use a fixed-dose of CEBPT (35<span class="elsevierStyleHsp" style=""></span>mL/kg/h compared with 75<span class="elsevierStyleHsp" style=""></span>mL/kg/h in septic patients with AKI). The study was conducted in 18 ICUs in France, Belgium and the Netherlands, looking for the impact of such therapy on mortality at 28 days. 140 patients (137 analyzed) were recruited but the study stopped early because of difficulties with the recruitment. The results of this study, and a recent meta-analysis based primarily on this study<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">59</span></a> show a lower than expected mortality in both groups (37.9% vs 40.8%), but similar between the two treatment groups (as expected because the study design).</p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Severe acute pancreatitis (SAP)</span><p id="par0250" class="elsevierStylePara elsevierViewall">Several authors have published studies in humans, with different designs, that seem to support the usefulness of HVHF on MODS after SAP. In a study by Jiang et al.,<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">60</span></a> with 37 patients comparing 1<span class="elsevierStyleHsp" style=""></span>L/h vs 4<span class="elsevierStyleHsp" style=""></span>L/h, as well as early (48<span class="elsevierStyleHsp" style=""></span>h) vs late (96<span class="elsevierStyleHsp" style=""></span>h) onset, survival at 14 days was significantly better in the higher dose group (94.4% vs 68.4%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.01) and a more noticeable hemodynamic improvement was also detected. A similar benefit was found in the early treatment group. Meanwhile, the group of Zhu et al. published in 2011 a study on 63 patients<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">61</span></a> in which the role of early beginning of HVHF (75<span class="elsevierStyleHsp" style=""></span>mL/kg/h on first 24<span class="elsevierStyleHsp" style=""></span>h of ICU admission) was evaluated in patients with SAP. The main result of the study was that early use of HVHF (for an average of 5 days) in patients with SAP improved survival at 28 days (81% vs 57.6%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.026). Oddly enough, no hemodynamic benefit was demonstrated.</p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">HVHF after post-resuscitation syndrome</span><p id="par0255" class="elsevierStylePara elsevierViewall">The similarities detected in MODS after recovered cardiac arrest with that of the sepsis patient motivated a randomized clinical trial to assess the usefulness of HVHF<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">62</span></a> in this setting. In this study, three groups were defined: one group was treated with a pulse of 8<span class="elsevierStyleHsp" style=""></span>h of HVHF (200<span class="elsevierStyleHsp" style=""></span>mL/kg/h); in a second group, a moderate therapeutic hypothermia was added, and the third group it was managed conservatively without EBPT or hypothermia. The results in mortality at six months showed a statistically significant improvement in patients receiving HVHF alone against HVHF plus hypothermia (45% vs 21%; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.026), and then both groups against the conventional medical management.</p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">HVHF in other types of SIRS</span><p id="par0260" class="elsevierStylePara elsevierViewall">Some promising studies have been conducted on the role of HVHF on patients with severe trauma or major burns<a class="elsevierStyleCrossRefs" href="#bib0690"><span class="elsevierStyleSup">63,64</span></a> an also on patients in shock after cardiac surgery, but in this last population, the HEROICS study<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">65</span></a> have shown negatives results. This was a randomized, multicenter clinical trial involving 224 patients randomized to receive early HVHF (80<span class="elsevierStyleHsp" style=""></span>mL/kg/h for 48<span class="elsevierStyleHsp" style=""></span>h), followed by a standard dose EBPT until the resolution of shock and acute renal dysfunction, or a standard dose EBPT (only in cases on AKI). Although no differences in mortality or duration of mechanical ventilation were detected, patients under HVHF showed a faster correction of metabolic acidosis and a tendency toward fastest reversal of shock, but also had more often hypophosphatemia, thrombocytopenia and metabolic alkalosis.</p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Alternative therapies</span><p id="par0265" class="elsevierStylePara elsevierViewall">In addition to HVHF, other forms of blood purification can be helpful: coupled filtration–adsorption, obtained by modifications on the structure and composition of the membranes; hemoperfusion with polymyxin-B or the use of membranes with a high sieving coefficient. These techniques are promising, but nowadays they are still experimental. Future research should address both the understanding of the pathophysiology of severe inflammatory conditions along the effect of the different modalities of blood purification, besides the development and application of technical improvements and a greater attention to their safety.</p></span></span></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Differential features in CEBPT application in pediatrics</span><p id="par0270" class="elsevierStylePara elsevierViewall">In children, the most common indication for CEBPT is fluid overload resistant to diuretics (early indication, anticipatory) and more specifically, although uncommon, a blood purification indication in the context of inborn errors of metabolism (hyperammonemia and organic acidemia),<a class="elsevierStyleCrossRefs" href="#bib0705"><span class="elsevierStyleSup">66–68</span></a> which are more efficiently purified by CEBPT than by peritoneal dialysis.</p><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">EBPT in pediatrics: key points</span><p id="par0275" class="elsevierStylePara elsevierViewall">The use of CEBPT in younger children differs significantly from adults because of the amount of blood that remains in the extracorporeal circuit (designed for adult size).<a class="elsevierStyleCrossRef" href="#bib0720"><span class="elsevierStyleSup">69</span></a><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">1.</span><p id="par0280" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Vascular access and blood flows</span>. Blood flow usually ranges between 2 and10<span class="elsevierStyleHsp" style=""></span>mL/kg/min<a class="elsevierStyleCrossRef" href="#bib0720"><span class="elsevierStyleSup">69</span></a> with a minimum of 30–50<span class="elsevierStyleHsp" style=""></span>mL/min, although flows above 80<span class="elsevierStyleHsp" style=""></span>mL/min are advisable to prevent extracorporeal circuit coagulation. These flows demand the use of a vascular access size of at least 6.5–8 Fr that can not be anatomically possible to insert in newborns and small infants.<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">70</span></a> These catheters occupy a larger proportion of the vessel diameter, so they are more prone to wall troubles, problems of venous return and thrombosis. When using regional anticoagulation strategies it is possible to maintain flows in the lower range without these concerns.<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">71</span></a></p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">2.</span><p id="par0285" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Selection of the filter in relation to weight</span> (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>). Although the extracorporeal circuits and filters try to adapt to pediatric size, they remain inadequate for the smallest patients. They might represent a volume of more than 10% in children under 10<span class="elsevierStyleHsp" style=""></span>kg and develop therapy overdose, despite prescribing in normal ranges (10–40<span class="elsevierStyleHsp" style=""></span>mL/kg/h).</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">3.</span><p id="par0290" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Blood heating</span>. Children lose heat more easily due to their greater body surface area in relation to their weight. This loss is increased by their diminished ability to compensate for it and is markedly enlarged by the oversized extracorporeal circuit when they are on CEBPT, so that the use of the heater is mandatory. It is usually placed in the return line but sometimes it is necessary to place another one in the input line. It is also possible to heat the fluids, but it is only effective for higher flows.</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">4.</span><p id="par0295" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Patient connection</span>. The amount of blood flow that remains in the extracorporeal circuit predisposes children to hypotension, hemodilution, and a high risk of cardiac arrest, especially in newborns and unstable infants at the time of connection, and principally when the priming volume of the circuit is discarded.<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">72</span></a> Therefore, we recommend administering fluids to the patient while the priming volume is being discarded, or to perform a second heparin-free priming that allows its introduction into the patient. Second priming with packed red blood cells is not recommended because of the risk of bradykinin release syndrome.</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">5.</span><p id="par0300" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Drugs dosage</span>. The volume of distribution of water-soluble drugs is higher in children than in adults because of significant changes in extracellular volume occurring in the first years of life.<a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">73</span></a> Additionally, we should take into account the significant increase in volume that represents the extracorporeal circuit, which is proportionally greater in the smallest patients. There are also differences in plasma protein binding and renal clearance of different drugs by age.<a class="elsevierStyleCrossRef" href="#bib0745"><span class="elsevierStyleSup">74</span></a></p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">6.</span><p id="par0305" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Dialytrauma</span>. Hypophosphatemia occurs despite “adequate” phosphates prescription in relation to patient weight. Nevertheless, it may be corrected using phosphorus-enriched solutions. Blood transfusion is usually needed in newborns and small infants whenever blood clots in the system.<a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">72</span></a></p></li></ul></p><p id="par0310" class="elsevierStylePara elsevierViewall">A study recently conducted in Italy has reported the successfully clinical use of a neonate CEBPT miniaturized machine especially designed for newborns and small infants (CARPEDIEM).<a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">75</span></a> Its main characteristics are a lower priming volume (<30<span class="elsevierStyleHsp" style=""></span>mL), miniaturized roller pumps and precise control of ultrafiltration using calibrated scales to the nearest gram. This miniaturized machine could represent a significant improvement for CEBPT in neonates and young infants, although more studies are needed to validate it.</p></span></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Funding source</span><p id="par0315" class="elsevierStylePara elsevierViewall">None.</p></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Contribution</span><p id="par0320" class="elsevierStylePara elsevierViewall">All authors have actively participated in the preparation of the article. Correspondence author has made the final editing of the manuscript. All authors have approved the final version of the article.</p></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Conflict of interests</span><p id="par0325" class="elsevierStylePara elsevierViewall">None, for all authors. Possible sources of funding have not been involved in the study design, data collection and in drafting the manuscript. It is a unique idea and work of the Nephrointensive Care Working Group of the Spanish society of intensive care (SEMICYUC).</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:14 [ 0 => array:3 [ "identificador" => "xres731997" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec735956" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres731998" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec735955" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Indications and timing of renal EBPT (Table 1)" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Modalities of renal extracorporeal blood purification therapies" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Dosing the extracorporeal purification therapy" ] ] ] 6 => array:3 [ "identificador" => "sec0025" "titulo" => "Other “non renal” possible indications for EBPT" "secciones" => array:10 [ 0 => array:2 [ "identificador" => "sec0030" "titulo" => "Role of CEBPT in fluid overload" ] 1 => array:2 [ "identificador" => "sec0035" "titulo" => "Acute hepatic failure" ] 2 => array:2 [ "identificador" => "sec0040" "titulo" => "Intoxications" ] 3 => array:2 [ "identificador" => "sec0045" "titulo" => "Metabolic acidosis" ] 4 => array:2 [ "identificador" => "sec0050" "titulo" => "Hyperthermia/hypothermia" ] 5 => array:2 [ "identificador" => "sec0055" "titulo" => "Electrolyte abnormality" ] 6 => array:2 [ "identificador" => "sec0060" "titulo" => "Crush syndrome" ] 7 => array:2 [ "identificador" => "sec0065" "titulo" => "Burns" ] 8 => array:2 [ "identificador" => "sec0070" "titulo" => "Brain edema" ] 9 => array:2 [ "identificador" => "sec0075" "titulo" => "Cardiac surgery" ] ] ] 7 => array:3 [ "identificador" => "sec0080" "titulo" => "High volume hemofiltration (HVHF)" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0085" "titulo" => "Pathophysiological basis" ] 1 => array:2 [ "identificador" => "sec0090" "titulo" => "Potential indications" ] 2 => array:2 [ "identificador" => "sec0095" "titulo" => "Preclinical studies and pilot studies" ] 3 => array:3 [ "identificador" => "sec0100" "titulo" => "Evidence" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0105" "titulo" => "Severe sepsis and septic shock" ] 1 => array:2 [ "identificador" => "sec0110" "titulo" => "Severe acute pancreatitis (SAP)" ] 2 => array:2 [ "identificador" => "sec0115" "titulo" => "HVHF after post-resuscitation syndrome" ] 3 => array:2 [ "identificador" => "sec0120" "titulo" => "HVHF in other types of SIRS" ] 4 => array:2 [ "identificador" => "sec0125" "titulo" => "Alternative therapies" ] ] ] ] ] 8 => array:3 [ "identificador" => "sec0130" "titulo" => "Differential features in CEBPT application in pediatrics" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0135" "titulo" => "EBPT in pediatrics: key points" ] ] ] 9 => array:2 [ "identificador" => "sec0140" "titulo" => "Funding source" ] 10 => array:2 [ "identificador" => "sec0145" "titulo" => "Contribution" ] 11 => array:2 [ "identificador" => "sec0150" "titulo" => "Conflict of interests" ] 12 => array:2 [ "identificador" => "xack243438" "titulo" => "Acknowledgments" ] 13 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-04-06" "fechaAceptado" => "2016-05-28" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec735956" "palabras" => array:8 [ 0 => "Extracorporeal purification" 1 => "AKI" 2 => "Dynamic purification" 3 => "Dose and timing of CEBPT" 4 => "Non-renal indications" 5 => "High volume" 6 => "HVHF" 7 => "Purification in children" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec735955" "palabras" => array:8 [ 0 => "Depuración extracorpórea" 1 => "FRA" 2 => "Dosificación dinámica" 3 => "Dosis e implementación de las TCDE" 4 => "Indicaciones no-renales" 5 => "Alto volumen" 6 => "HFAV" 7 => "Depuración en pediatría" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">We maintain a dynamic position on extracorporeal blood purification therapies (EBPT). Continuous therapies are of choice in the hemodynamically unstable patient. We recommend their early introduction in the course of the disease, and starting with a dose of 30–35<span class="elsevierStyleHsp" style=""></span>mL/kg/h. Above all, however, daily re-evaluation is required of the hemodynamic and metabolic situation and water balance of our patients in order to allow dynamic dose adjustment. Some data suggest that continuous EBPT can favorably influence the clinical course of our patients, even in the absence of acute kidney injury. The potential usefulness of hemofiltration at doses higher than the conventional doses (continuous ultrafiltration >50<span class="elsevierStyleHsp" style=""></span>mL/kg/h or pulses of at least 4<span class="elsevierStyleHsp" style=""></span>h a day to more than 100<span class="elsevierStyleHsp" style=""></span>doses<span class="elsevierStyleHsp" style=""></span>mL/kg/h) for achieving blood purification has also been commented. We review the possible indications of this technique, together with the peculiarities of implementing these therapies in children.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Creemos que las técnicas de depuración extracorpórea deben seguir un planteamiento dinámico. Las técnicas continuas son de elección en los pacientes hemodinámicamente inestables. Recomendamos un inicio precoz en el curso de la enfermedad y comenzar con una dosis de 30-35<span class="elsevierStyleHsp" style=""></span>ml/kg/h. Pero, sobre todo, deberemos hacer una reevaluación diaria de la situación del paciente (hemodinámica, metabólica y del estado hidroelectrolítico) para ajustar la dosis de forma dinámica. Algunos datos evidencian que las técnicas de depuración extracorpórea continuas pueden influir favorablemente en la evolución del paciente crítico, independientemente de su función renal. Se comenta también la potencial utilidad de usar dosis de depuración superiores a las convencionales (hemofiltración superior a 50<span class="elsevierStyleHsp" style=""></span>ml/kg/h o pulsos de al menos 4<span class="elsevierStyleHsp" style=""></span>h diarias de más de 100<span class="elsevierStyleHsp" style=""></span>ml/kg/h). Revisamos, asimismo, otras posibles indicaciones de las técnicas de depuración extracorpórea, así como las peculiaridades de su aplicación en pediatría.</p></span>" ] ] "multimedia" => array:7 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 4126 "Ancho" => 2339 "Tamanyo" => 554192 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Algorithm for initiation of CEBPT in critically ill patients. AKI: Acute kidney injury. DM: Mellitus diabetes. CRF: Chronic renal failure. CHF: Congestive heart failure. MV: Mechanical ventilation. SIRS: systemic inflammatory response syndrome. NSAI: nonsteroidal anti-inflammatory. ACE: converting enzyme inhibitors. ATB: antibiotics. CrCl: Creatinine clearance. Cr. Creatinine. EGDT: Early goal-directed therapy. RRT: extracorporeal blood purification therapies. K+: Potassium. APE: Acute pulmonary edema. CRRT: Continuous extracorporeal blood purification therapies. IHD: Intermittent dialysis. SLEDD: Sustained low-efficiency daily diafiltration. CVVHDF: Continuous venovenous hemodiafiltration. Q: Flow. FF: Filtration fraction.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 3543 "Ancho" => 2366 "Tamanyo" => 417845 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Algorithm for maintenance and withdrawal of CEBPT in critically ill patients. K+: Potassium. P: Phosphorus. BE: base excess. T°: Temperature. CVP: central venous pressure. PAWP: pulmonary wedge pressure. SVV: stroke volume variation. PPV: Variation in pulmonary pressure. GEDI: Overall volume index at the end of diastole. ELWI: Indexed extravascular lung water. Q<span class="elsevierStyleInf">efl</span>: Effluent flow. ΔSOFA: SOFA Score increase. CPK: Creatine fosfoquinase. IAP: Acute pulmonary edema.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 4253 "Ancho" => 2642 "Tamanyo" => 568755 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">HVHF management algorithm in unstable critically ill patients. SIRS: systemic inflammatory response syndrome. CVP: central venous pressure. S<span class="elsevierStyleInf">cv</span>O2: Venous oxygen saturation. ICU: Intensive Care Unit. SOFA: SOFA Score. AKI: Acute kidney injury. CRRT: Continuous extracorporeal blood purification therapies. NA/NE: Noradrenaline. CVVHDF: Continuous venovenous hemodiafiltration. Q<span class="elsevierStyleInf">efl</span>: Effluent flow. EBPT: extracorporeal blood purification therapies. CVVH: Continuous venovenous hemofiltration. HVHF: high volume hemofiltration. Q<span class="elsevierStyleInf">subst:</span> Effluent flow. EBPT: Extracorporeal blood purification therapies.</p>" ] ] 3 => array:6 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">AKI: acute kidney injury. EBPT: extracorporeal blood purification therapies. CrCl: creatinine clearance. Cr: creatinine. K+: potassium. APE: acute pulmonary edema. CEBPT: continuous extracorporeal blood purification therapies. IHD: intermittent dialysis. CVVHDF: continuous venovenous hemodiafiltration. CVVH: continuous venovenous hemofiltration.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Decalogue for EBPT in AKI \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">1. AKI is a dynamic process that requires a dynamic approach. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2. Initiation of EBPT in AKI should not be delayed but should start early. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3. We propose to begin the EBPT if any of the following criteria are met: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>I. Oliguria <200<span class="elsevierStyleHsp" style=""></span>mL/12<span class="elsevierStyleHsp" style=""></span>h. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>II. Urea >120<span class="elsevierStyleHsp" style=""></span>mg/dL and/or CrCl >25% and/or Cr >1.5<span class="elsevierStyleItalic">x</span>. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>III. K+ >6<span class="elsevierStyleHsp" style=""></span>mEq/L. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IV. Life-threatening situation: APE; Uremia; severe acidosis. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">4. Studies on dose have not taken into consideration the dynamic nature of AKI. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">5. At least 10% of the scheduled dose is not delivered. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">6. We suggest starting with a dose of at least 30<span class="elsevierStyleHsp" style=""></span>mL/kg/h. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">7. Regardless of the chosen dose, we must monitor its effect and adjust accordingly. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">8. The choice of modality (CEBPT vs IHD) depends on the type of patient, the available infrastructure and our own experience. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">9. In the critically ill patient (especially if hemodynamically unstable) CEBPT seems the ideal modality. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">10. For a due dose, CVVHDF and CVVH are comparable so, in general, we should start with CVVHDF in order to optimize filters life. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1206927.png" ] ] ] ] ] 4 => array:6 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">MODS: multiple organ dysfunction syndrome. GRADE: methodology for formulating and grading recommendations in clinical practice.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Other possible indications for EBPT \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Grade \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">MODS:</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Hemodynamic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Respiratory \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Cardiac failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Fulminant hepatic failure \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Crush syndrome \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">C \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Intoxications \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Brain edema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">B \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Metabolic acidosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Electrolyte abnormality \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Hypotermia/hypertermia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">A \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1206926.png" ] ] ] ] ] 5 => array:6 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">HVHF: high volume hemofiltration. CVVH: continuous veno-venous hemofiltration.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Definition HVHF \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Conventional dose: ≤50<span class="elsevierStyleHsp" style=""></span>mL/kg/h \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• High volume: \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Continuous: >50<span class="elsevierStyleHsp" style=""></span>mL/kg/h \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Pulsed: >100<span class="elsevierStyleHsp" style=""></span>mL/kg/day for ≥4<span class="elsevierStyleHsp" style=""></span>h/day, followed by conventional dose CVVH \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1206929.png" ] ] ] ] ] 6 => array:8 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">CEBPT: continuous extracorporeal blood purification therapies.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Monitor-filter \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Surface (m<span class="elsevierStyleSup">2</span>) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Blood volume (filter<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>circuit) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Patient weight \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PRISMA M10 (Gambro) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.042<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">75<span class="elsevierStyleHsp" style=""></span>mL* (*25<span class="elsevierStyleHsp" style=""></span>mL hotline) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2–15<span class="elsevierStyleHsp" style=""></span>kg* (*discouraged by multiple coagulation system) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Prismaflex HF20 (Gambro) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.2<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">60<span class="elsevierStyleHsp" style=""></span>mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3–15<span class="elsevierStyleHsp" style=""></span>kg* (*according to data sheet >8<span class="elsevierStyleHsp" style=""></span>kg) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Aquarius-Aquamax HF03 (Baxter) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.3<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">96<span class="elsevierStyleHsp" style=""></span>mL* (*circuit aqualine S, pediatric: 64) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5–20<span class="elsevierStyleHsp" style=""></span>kg \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Prismaflex M60 (Gambro) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.6<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">93<span class="elsevierStyleHsp" style=""></span>mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10–30<span class="elsevierStyleHsp" style=""></span>kg* (*according to data sheet >11<span class="elsevierStyleHsp" style=""></span>kg) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Aquarius-Aquamax HF07 (Baxter) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.7<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">118<span class="elsevierStyleHsp" style=""></span>mL* (*circuit aqualine S, pediatric: 64) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">20–40<span class="elsevierStyleHsp" style=""></span>kg \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Prismaflex M100 (Gambro) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.9<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">152<span class="elsevierStyleHsp" style=""></span>mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">≥30<span class="elsevierStyleHsp" style=""></span>kg \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Aquarius-Aquamax HF12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.2<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">178* (*normal circuit aqualine N, 105<span class="elsevierStyleHsp" style=""></span>mL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>40<span class="elsevierStyleHsp" style=""></span>kg \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Prismaflex M150 (Gambro) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.5<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">189<span class="elsevierStyleHsp" style=""></span>mL \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">≥50<span class="elsevierStyleHsp" style=""></span>kg \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Aquarius-Aquamax HF19 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.9<span class="elsevierStyleHsp" style=""></span>m<span class="elsevierStyleSup">2</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">214* (*normal circuit aqualine N, 105<span class="elsevierStyleHsp" style=""></span>mL) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">>60<span class="elsevierStyleHsp" style=""></span>kg \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1206928.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">CEBPT filters used in pediatrics.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:75 [ 0 => array:3 [ "identificador" => "bib0380" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiología del fracaso renal agudo en las UCI españolas. Estudio prospectivo-multicéntrico FRAMI" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Grupo de Trabajo FRAMI" "etal" => false "autores" => array:4 [ 0 => "M. Herrera Gutierrez" 1 => "G. Seller Pérez" 2 => "J. Maynar Moliner" 3 => "J.A. Sanchez-Izquierdo Riera" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Med Intensiva" "fecha" => "2006" "volumen" => "30" "paginaInicial" => "260" "paginaFinal" => "267" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16949000" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0385" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized, controlled trial of early versus late initiation of dialysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.A. Cooper" 1 => "P. Branley" 2 => "L. Bulfone" 3 => "J.F. Collins" 4 => "J.C. Craig" 5 => "M.B. Fraenkel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1000552" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2010" "volumen" => "363" "paginaInicial" => "609" "paginaFinal" => "619" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20581422" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0390" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hemofiltración venovenosa continua en pacientes críticos" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.A. Sanchez-Izquierdo Riera" 1 => "M.J. Lozano Quintana" 2 => "A. Ambros Checa" 3 => "J.L. Perez Vela" 4 => "R. Caballero Cubedo" 5 => "E. Alted López" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Med Intensiva" "fecha" => "1995" "volumen" => "19" "paginaInicial" => "171" "paginaFinal" => "176" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0395" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (BEST Kidney) investigators" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Uchino" 1 => "R. Bellomo" 2 => "H. Morimatsu" 3 => "S. Morgera" 4 => "M. Schetz" 5 => "I. Tan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int Care Med" "fecha" => "2007" "volumen" => "33" "paginaInicial" => "1563" "paginaFinal" => "1570" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0400" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "KDIGO clinical practice guidelines for acute kidney injury" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Kidney Disease outcomes quality initiative" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Kidney Int Suppl" "fecha" => "2012" "volumen" => "2" "paginaInicial" => "1" "paginaFinal" => "138" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1057668" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0405" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 2: Renal replacement therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Jorres" 1 => "S. John" 2 => "A. Lewington" 3 => "P.M. ter Wee" 4 => "R. Vanholder" 5 => "W. Van Viesen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/ndt/gft297" "Revista" => array:6 [ "tituloSerie" => "Nephrol Dial Transplant" "fecha" => "2013" "volumen" => "28" "paginaInicial" => "2940" "paginaFinal" => "2945" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24121762" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0410" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.J. Karvellas" 1 => "M.R. Farhat" 2 => "I. Sajjad" 3 => "S.S. Mogensen" 4 => "A.A. Leung" 5 => "R. Wald" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/cc10061" "Revista" => array:5 [ "tituloSerie" => "Crit Care" "fecha" => "2011" "volumen" => "15" "paginaInicial" => "R72" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21352532" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0415" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Timing of renal replacement therapy initiation by AKIN classification system" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.T. Leite" 1 => "E. Macedo" 2 => "S.M. Pereira" 3 => "S.R.C. Bandeira" 4 => "P.H.S. Pontes" 5 => "A.S. Garcia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/cc12593" "Revista" => array:5 [ "tituloSerie" => "Crit Care" "fecha" => "2013" "volumen" => "17" "paginaInicial" => "R62" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23548002" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0420" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Wald" 1 => "N.K. Adhikari" 2 => "O.M. Smith" 3 => "M.A. Weir" 4 => "K. Pope" 5 => "A. Cohen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ki.2015.184" "Revista" => array:6 [ "tituloSerie" => "Kidney Int" "fecha" => "2015" "volumen" => "88" "paginaInicial" => "897" "paginaFinal" => "904" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26154928" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0425" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Earlier-start versus usual-start dialysis in patients with community-acquired acute kidney injury: a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.E. Jamale" 1 => "N.K. Hase" 2 => "M. Kulkarni" 3 => "K.J. Pradeep" 4 => "K. Vaibhav" 5 => "J. Sunil" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.ajkd.2013.06.012" "Revista" => array:6 [ "tituloSerie" => "Am J Kidney Dis" "fecha" => "2013" "volumen" => "62" "paginaInicial" => "1116" "paginaFinal" => "1121" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23932821" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0430" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Renal replacement therapy in acute kidney injury: controversy and consensus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Ronco" 1 => "Z. Ricci" 2 => "D. De Baker" 3 => "J.A. Kellum" 4 => "F.S. Taccone" 5 => "M. Joannidis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13054-015-0850-8" "Revista" => array:5 [ "tituloSerie" => "Crit Care" "fecha" => "2015" "volumen" => "19" "paginaInicial" => "146" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25887923" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0435" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Plasma neutrophil gelatinase-associated lipocalin predicts recovery from acute kidney injury following community-acquired pneumonia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Srisawat" 1 => "R. Murugan" 2 => "M. Lee" 3 => "L. Kong" 4 => "M. Carter" 5 => "D.C. Angus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ki.2011.160" "Revista" => array:6 [ "tituloSerie" => "Kidney Int" "fecha" => "2011" "volumen" => "80" "paginaInicial" => "545" "paginaFinal" => "552" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21677634" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0440" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Urinary biomarkers and renal recovery in critically ill patients with renal support" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "N. Srisawat" 1 => "X. Wen" 2 => "M. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2215/CJN.11261210" "Revista" => array:6 [ "tituloSerie" => "Clin J Am Soc Nephrol" "fecha" => "2011" "volumen" => "6" "paginaInicial" => "1815" "paginaFinal" => "1823" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21757640" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0445" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Development and standardization of a furosemide stress test to predict the severity of acute kidney injury" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.S. Chawla" 1 => "D.L. Davison" 2 => "E. Brasha-Mitchell" 3 => "J.L. Koyner" 4 => "J.M. Arthur" 5 => "A.D. Shaw" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/cc13015" "Revista" => array:5 [ "tituloSerie" => "Crit Care" "fecha" => "2013" "volumen" => "17" "paginaInicial" => "R207" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24053972" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0450" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomized controlled trial (AKIKI)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Gaudry" 1 => "D. Hajage" 2 => "F. Schortgen" 3 => "L. Martin-Lefevre" 4 => "F. Tubach" 5 => "B. Pons" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13063-015-0718-x" "Revista" => array:5 [ "tituloSerie" => "Trials" "fecha" => "2015" "volumen" => "16" "paginaInicial" => "170" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25902813" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0455" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in sEBPTic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S.D. Barbar" 1 => "C. Binquet" 2 => "M. Monchi" 3 => "R. Bruyere" 4 => "J.P. Quenot" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1745-6215-15-270" "Revista" => array:5 [ "tituloSerie" => "Trials" "fecha" => "2014" "volumen" => "15" "paginaInicial" => "270" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24998258" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0460" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cuándo y Cómo iniciar las TDE en pacientes con fracaso renal agudo" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "G. Leoz Abellanas" 1 => "J.A. Sánchez-Izquierdo Riera" 2 => "J. Maynar Moliner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:5 [ "isbn" => "9788484739951" "titulo" => "Nefrorrápid" "paginaInicial" => "79" "paginaFinal" => "83" "serieFecha" => "2012" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0465" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Uchino" 1 => "R. Bellomo" 2 => "H. Morimatsu" 3 => "S. Morgera" 4 => "M. Schetz" 5 => "I. Tan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/CCM.0b013e3181a38241" "Revista" => array:6 [ "tituloSerie" => "Crit Care Med" "fecha" => "2009" "volumen" => "37" "paginaInicial" => "2576" "paginaFinal" => "2582" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19623048" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0470" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intensity of renal support in critically ill patients with acute kidney injury" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.M. Palevsky" 1 => "J.H. Zhang" 2 => "T.Z. O’Connor" 3 => "G.M. Chertow" 4 => "S.T. Crowley" 5 => "D. Choudhury" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa0802639" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2008" "volumen" => "359" "paginaInicial" => "7" "paginaFinal" => "20" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18492867" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0475" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Handling continuous renal replacement therapy-related adverse effects in intensive care unit patients: the dialytrauma concept" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Maynar Moliner" 1 => "P.M. Honoré" 2 => "J.A. Sánchez-Izquierdo Riera" 3 => "M.E. Herrera Gutierrez" 4 => "H.D. Spapen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000342064" "Revista" => array:6 [ "tituloSerie" => "Blood Purif" "fecha" => "2012" "volumen" => "34" "paginaInicial" => "177" "paginaFinal" => "185" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23095418" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0480" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Cómo finalizar una TDE en AKI" "etal" => false "autores" => array:3 [ 0 => "G. Leoz Abellanas" 1 => "J.A. Sanchez-Izquierdo Riera" 2 => "J. Maynar Moliner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:5 [ "isbn" => "9788484739951" "titulo" => "Nefrorrapid: Una guía de respuesta rápida para el manejo del paciente crítico con Disfunción Renal Aguda" "paginaInicial" => "87" "paginaFinal" => "92" "serieFecha" => "2012" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0485" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for Acute Kidney Injury" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R.G. Langham" 1 => "R. Bellomo" 2 => "V. D’ Intini" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Nephrology (Carlton)" "fecha" => "2014" "volumen" => "19" "paginaInicial" => "261" "paginaFinal" => "265" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0490" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fluid overload in critically ill patients with acute kidney injury" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Cerda" 1 => "G. Sheinfeld" 2 => "C. Ronco" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Blood Purif" "fecha" => "2010" "volumen" => "29" "paginaInicial" => "11" "paginaFinal" => "18" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0495" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The influence of volume management on outcome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.M. Bagshaw" 1 => "R. Bellomo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MCC.0b013e3282e2a978" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Crit Care" "fecha" => "2007" "volumen" => "13" "paginaInicial" => "541" "paginaFinal" => "548" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17762233" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0500" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute decompensated heart failure and the cardiorenal syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K.V. Liang" 1 => "A.W. Williams" 2 => "E.L. Greene" 3 => "M.M. Redfield" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.CCM.0000296270.41256.5C" "Revista" => array:7 [ "tituloSerie" => "Crit Care Med" "fecha" => "2008" "volumen" => "36" "numero" => "Suppl. 1" "paginaInicial" => "S75" "paginaFinal" => "S88" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18158481" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0505" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daily hemofiltration in severe heart failure" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L. Iorio" 1 => "R. Simonelli" 2 => "R.G. Nacca" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Kidney Int" "fecha" => "1997" "volumen" => "51" "paginaInicial" => "S62" "paginaFinal" => "S65" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0510" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ultrafiltration versus usual care for hospitalizad patients with Herat failure (RAPID-CHF trial)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "B.A. Bart" 1 => "A. Boyle" 2 => "A.J. Bank" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2005.05.098" "Revista" => array:6 [ "tituloSerie" => "JACC" "fecha" => "2005" "volumen" => "46" "paginaInicial" => "2043" "paginaFinal" => "2046" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16325039" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0515" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.R. Costanzo" 1 => "M.E. Guglin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2006.07.073" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2007" "volumen" => "49" "paginaInicial" => "675" "paginaFinal" => "683" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17291932" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0520" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of ULTRAfiltration vs. DIureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Giglioli" 1 => "D. Landi" 2 => "E. Cecchi" 3 => "M. Chiostri" 4 => "G.F. Gensini" 5 => "S. Valente" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur J Heart Fail" "fecha" => "2011" "volumen" => "13" "paginaInicial" => "337" "paginaFinal" => "346" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21131387" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0525" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ultrafiltration in decompensated heart failure with cardiorrenal syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.A. Bart" 1 => "S.R. Goldsmith" 2 => "K.L. Lee" 3 => "M.M. Givertz" 4 => "C.M. O’Connor" 5 => "D.A. Bull" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1210357" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2012" "volumen" => "367" "paginaInicial" => "2296" "paginaFinal" => "2304" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23131078" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0530" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Davenport" 1 => "E.J. Will" 2 => "A.M. Davidson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Crit Care Med" "fecha" => "1993" "volumen" => "21" "paginaInicial" => "328" "paginaFinal" => "338" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8440100" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0535" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Poisonings and overdoses in the intensive care unit: general and specific management issues" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.L. Zimmerman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.CCM.0000100123.50896.F0" "Revista" => array:6 [ "tituloSerie" => "Crit Care Med" "fecha" => "2003" "volumen" => "31" "paginaInicial" => "2794" "paginaFinal" => "2801" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14668617" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0540" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the Extracorporeal Treatments in Poisoning Workgroup" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.P. Calello" 1 => "K.D. Liu" 2 => "T.J. Wiegand" 3 => "D.M. Roberts" 4 => "V. Lavergne" 5 => "S. Gosselin" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Crit Care Med" "fecha" => "2015" "volumen" => "43" "paginaInicial" => "1715" "paginaFinal" => "1730" ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0545" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of metformin-associated lactic acidosis by continuous renal replacement therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "G. Keller" 1 => "M. Cour" 2 => "R. Hernu" 3 => "J. Illinger" 4 => "D. Robert" 5 => "L. Argaud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0023200" "Revista" => array:5 [ "tituloSerie" => "PLoS ONE" "fecha" => "2011" "volumen" => "6" "paginaInicial" => "e23200" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21853087" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0550" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lactic acidosis treated with continuous hemodiafiltration and regional citrate anticoagulation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "B. Kirschbaum" 1 => "M. Galishoff" 2 => "H.D. Reines" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Crit Care Med" "fecha" => "1992" "volumen" => "20" "paginaInicial" => "319" "paginaFinal" => "353" ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0555" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Continuous renal replacement therapy in the intensive care unit" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Bellomo" 1 => "C. Ronco" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int Care Med" "fecha" => "1999" "volumen" => "25" "paginaInicial" => "781" "paginaFinal" => "789" ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0560" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rhabdomyolysis and acute kidney injury" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "X. Bosch" 1 => "E. Poch" 2 => "J. Grau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra0801327" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2009" "volumen" => "361" "paginaInicial" => "62" "paginaFinal" => "72" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19571284" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0565" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment by continuous renal replacement therapy in patients with burns injuries" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Hladik" 1 => "J. Tymonová" 2 => "T. Zaoral" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Chir Plast" "fecha" => "2001" "volumen" => "43" "paginaInicial" => "21" "paginaFinal" => "25" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11370254" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0570" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intracranial pressure fluctuation during hemodialysis in renal failure patients with intracranial hemorrhage" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.M. Lin" 1 => "J.W. Lin" 2 => "J.T. Tsai" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Neurochir Suppl" "fecha" => "2008" "volumen" => "101" "paginaInicial" => "141" "paginaFinal" => "144" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18642649" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0575" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute kidney injury following cardiac surgery: impact of early versus late haemofiltration on morbidity and mortality" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Elahi" 1 => "S. Asopa" 2 => "A. Pflueger" 3 => "N. Hakim" 4 => "B. Matata" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejcts.2008.12.019" "Revista" => array:6 [ "tituloSerie" => "Eur J Cardiothorac Surg" "fecha" => "2009" "volumen" => "35" "paginaInicial" => "854" "paginaFinal" => "863" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19216088" "web" => "Medline" ] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0580" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hemofiltration during cardiopulmonary bypass" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D. Journois" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Kidney Int" "fecha" => "1998" "volumen" => "53" "paginaInicial" => "S174" "paginaFinal" => "S177" ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0585" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The first international consensus conference on continuous renal replacement therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.A. Kellum" 1 => "R.L. Mehta" 2 => "D.C. Angus" 3 => "P. Palevsky" 4 => "C. Ronco" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1046/j.1523-1755.2002.00613.x" "Revista" => array:6 [ "tituloSerie" => "Kidney Int" "fecha" => "2002" "volumen" => "62" "paginaInicial" => "1855" "paginaFinal" => "1863" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12371989" "web" => "Medline" ] ] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0590" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Report of the working party on high volume hemofiltration including definitions and classification" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P.M. Honore" 1 => "O. Joannes-Boyau" 2 => "T. Kotulak" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2007" "editorial" => "Paper presented at: proc 2nd Czech conference on critical care nephrology" "editorialLocalizacion" => "Pardubice, Czech Republic, April 18–19" ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0595" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-volume hemofiltration in the intensive care unit: a blood purification therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T. Rimmelé" 1 => "J.A. Kellum" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/ALN.0b013e318256f0c0" "Revista" => array:6 [ "tituloSerie" => "Anesthesiology" "fecha" => "2012" "volumen" => "116" "paginaInicial" => "1377" "paginaFinal" => "1387" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22534247" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0600" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High volume hemofiltration in septic shock" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C.M. Romero" 1 => "P. Downey" 2 => "G. Hernández" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.medin.2009.10.001" "Revista" => array:6 [ "tituloSerie" => "Med Intensiva" "fecha" => "2010" "volumen" => "34" "paginaInicial" => "345" "paginaFinal" => "352" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20153085" "web" => "Medline" ] ] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0605" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety management of a clinical process using failure mode and effect analysis: continuous renal replacement therapies in intensive care unit patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.A. Sanchez-Izquierdo-Riera" 1 => "E. Molano-Alvarez" 2 => "I. Saez-de la Fuente" 3 => "J. Maynar-Moliner" 4 => "H. Marín-Mateos" 5 => "S. Chacón-Alves" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "ASAIO J" "fecha" => "2016" "volumen" => "62" "paginaInicial" => "74" "paginaFinal" => "79" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26418206" "web" => "Medline" ] ] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0610" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.F. Grootendorst" 1 => "E.F. van Bommel" 2 => "B. van der Hoven" 3 => "A.L.M. van Osta" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int Care Med" "fecha" => "1992" "volumen" => "18" "paginaInicial" => "235" "paginaFinal" => "240" ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0615" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.F. Grootendorst" 1 => "E.F. van Bommel" 2 => "L.A. van Leegoed" 3 => "A.L.M. van Osta" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Crit Care" "fecha" => "1993" "volumen" => "8" "paginaInicial" => "161" "paginaFinal" => "169" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8275161" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0620" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery. Effects on hemostasis, cytokines, and complement components" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D. Journois" 1 => "P. Povard" 2 => "W.J. Greeley" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Anesthesiology" "fecha" => "1994" "volumen" => "81" "paginaInicial" => "1181" "paginaFinal" => "1189" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7978476" "web" => "Medline" ] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0625" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-volume haemofiltration in human septic shock" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Cole" 1 => "R. Bellomo" 2 => "D. Journois" 3 => "P. Davenport" 4 => "I. Baldwin" 5 => "P. Tipping" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int Care Med" "fecha" => "2001" "volumen" => "27" "paginaInicial" => "978" "paginaFinal" => "986" ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0630" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Boussekey" 1 => "A. Chiche" 2 => "K. Faure" 3 => "P. Devos" 4 => "B. Guery" 5 => "T. d’Escriban" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int Care Med" "fecha" => "2008" "volumen" => "34" "paginaInicial" => "1646" "paginaFinal" => "1653" ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0635" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Outcome of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "H.M. Oudemans-Van Straaten" 1 => "R.J. Bosman" 2 => "J.I. van der Spoel" 3 => "D.F. Zandstra" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int Care Med" "fecha" => "1999" "volumen" => "25" "paginaInicial" => "814" "paginaFinal" => "821" ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0640" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.M. Honoré" 1 => "J. Jamez" 2 => "M. Wauthier" 3 => "P.A. Lee" 4 => "E. Thierry" 5 => "P. Bruno" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Crit Care Med" "fecha" => "2000" "volumen" => "28" "paginaInicial" => "3581" "paginaFinal" => "3587" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11098957" "web" => "Medline" ] ] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0645" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "O. Joannes-Boyau" 1 => "R. Rapaport St Bazin" 2 => "C. Fleureau" 3 => "G. Janvier" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "ASAIO J" "fecha" => "2004" "volumen" => "50" "paginaInicial" => "102" "paginaFinal" => "109" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14763500" "web" => "Medline" ] ] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0650" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Ratanarat" 1 => "A. Brendolan" 2 => "P. Piccinni" 3 => "M. Dan" 4 => "G. Salvatori" 5 => "Z. Ricci" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/cc3529" "Revista" => array:6 [ "tituloSerie" => "Crit Care" "fecha" => "2005" "volumen" => "9" "paginaInicial" => "R294" "paginaFinal" => "R302" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16137340" "web" => "Medline" ] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0655" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early isovolemic haemofiltration in oliguric patients with septic shock" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Piccinni" 1 => "M. Dan" 2 => "S. Barbacini" 3 => "R. Carraro" 4 => "E. Lieta" 5 => "S. Marafon" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int Care Med" "fecha" => "2006" "volumen" => "32" "paginaInicial" => "80" "paginaFinal" => "86" ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0660" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Cuándo y Cómo iniciar las TDE en la Sépsis" "etal" => false "autores" => array:3 [ 0 => "J.A. Sanchez-Izquierdo Riera" 1 => "L. Abellanas" 2 => "J. Maynar Moliner" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:5 [ "isbn" => "9788484739951" "titulo" => "Nefrorrapid: Una guía de respuesta rápida para el manejo del paciente crítico con Disfunción Renal Aguda" "paginaInicial" => "93" "paginaFinal" => "98" "serieFecha" => "2012" ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0665" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Joannes-Boyau" 1 => "P.M. Honoré" 2 => "P. Perez" …3 ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int Care Med" "fecha" => "2013" "volumen" => "39" "paginaInicial" => "1535" "paginaFinal" => "1546" ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0670" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/cc13184" "Revista" => array:5 [ "tituloSerie" => "Crit Care" "fecha" => "2014" "volumen" => "18" "paginaInicial" => "R7" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0675" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of continuous veno-venous hemofiltration on the course of acute pancreatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "World J Gastroenterol" "fecha" => "2005" "volumen" => "11" "paginaInicial" => "4815" "paginaFinal" => "4821" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0680" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adjunctive continuous high-volume hemofiltration in patients with acute severe pancreatitis. A prospective nonrandomized study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MPA.0b013e3181f83019" "Revista" => array:6 [ "tituloSerie" => "Pancreas" "fecha" => "2011" "volumen" => "40" "paginaInicial" => "109" "paginaFinal" => "113" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0685" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High-volume hemofiltration after out-of-hospital cardiac arrest a randomized study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2005.04.039" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2005" "volumen" => "46" "paginaInicial" => "432" "paginaFinal" => "437" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0690" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of continuous hemofiltration on hemodynamics of trauma patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Surgery" "fecha" => "1997" "volumen" => "122" "paginaInicial" => "902" "paginaFinal" => "908" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0695" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cytokines clearance during venovenous hemofiltration in the trauma patient" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Kidney Dis" "fecha" => "1997" "volumen" => "30" "paginaInicial" => "483" "paginaFinal" => "488" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0700" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early high-volume hemofiltration versus standard care for post-cardiac surgery shock. The HEROICS study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201503-0516OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2015" "volumen" => "192" "paginaInicial" => "1179" "paginaFinal" => "1190" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0705" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute kidney injury in children" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00467-008-1074-9" "Revista" => array:6 [ "tituloSerie" => "Pediatr Nephrol" "fecha" => "2009" "volumen" => "24" "paginaInicial" => "253" "paginaFinal" => "263" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0710" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An update and review of acute kidney injury in pediatrics" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ …4] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/PCC.0b013e3181fe2e0b" "Revista" => array:6 [ "tituloSerie" => "Pediatr Crit Care Med" "fecha" => "2011" "volumen" => "12" "paginaInicial" => "339" "paginaFinal" => "347" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0715" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2215/CJN.03200906" "Revista" => array:6 [ "tituloSerie" => "Clin J Am Soc Nephrol" "fecha" => "2007" "volumen" => "2" "paginaInicial" => "732" "paginaFinal" => "738" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0720" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The evolution of pediatric continuous renal replacement therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000363204" "Revista" => array:6 [ "tituloSerie" => "Nephron Clin Pract" "fecha" => "2014" "volumen" => "127" "paginaInicial" => "172" "paginaFinal" => "175" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0725" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical review: alternative vascular access techniques for continuous hemofiltration" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ …3] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/cc5035" "Revista" => array:6 [ "tituloSerie" => "Crit Care" "fecha" => "2006" "volumen" => "10" "paginaInicial" => "230" "paginaFinal" => "235" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0730" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anticoagulación regional con citrato en las técnicas de depuración extrarrenal continuas" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "An Pediatr (Barc)" "fecha" => "2012" "volumen" => "76" "paginaInicial" => "49" "paginaFinal" => "52" ] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0735" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Complications of continuous renal replacement therapy in critically ill children: a prospective observational evaluation study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ …6] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/cc8172" "Revista" => array:5 [ "tituloSerie" => "Crit Care" "fecha" => "2009" "volumen" => "13" "paginaInicial" => "R184" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0740" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Body water compartments in children: changes during growth and related changes in body composition" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ …1] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pediatrics" "fecha" => "1961" "volumen" => "28" "paginaInicial" => "169" "link" => array:1 [ 0 => array:2 [ …2] ] ] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0745" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug dosing during intermittent hemodialysis and continuous renal replacement therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ …5] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Pediatr Drugs" "fecha" => "2004" "volumen" => "6" "paginaInicial" => "45" "paginaFinal" => "66" ] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0750"